Nicola Mining Receives Multi-Year Area Based Exploration Permit for Its Mine-Permitted Treasure Mountain Silver Project
Vancouver, British Columbia--(Newsfile Corp. - June 9, 2025) - Nicola Mining Inc. (TSX: NIM) (OTCQB: HUSIF) (FSE: HLIA) (the "Company" or "Nicola") is pleased to announce that it has received a multi-year area-based exploration permit, Permit Number MX-15-121 (the "MYAB Permit") on June 4th, 2025. The MYAB Permit allows Nicola to conduct extensive exploration on its wholly owned Treasure Mountain Silver Project1 (the "Treasure Mountain"), a fully permitted silver mine (Permit 239) located 30 km northeast of Hope and about a 3-hour drive from Vancouver, British Columbia (Fig. 1).
Figure 1. Treasure Mountain locationTo view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/4873/254869_f589e05a049e09e2_001full.jpg
Receipt of the MYAB Permit, follows the Company's August 30th, 2024, announcement that it had received a ten-year mining lease extension (the "Extension") for Treasure Mountain2 under its M-239 permit. The Extension is valid through April 26, 2032, and receipt of the MYAB Permit positions the Company to leverage both mining and exploration options.
Treasure Mountain consists of an historic underground silver mine with a resource estimate in accordance with CIM definition standards3 and exploration upside to the north and west of the historic mine. The MB Zone is approximately 800 m northwest of the current mine workings on undrilled northern flank of the mountain. The Cal Vein was discovered at this location in 2010 and return a surface sample grading as high as 9,221g/t Ag, 1.02% Cu, 1.14% Pb and 1.03% Zn4. Subsequent soil sampling was conducted in 2011/2012 and 2013 with encouraging results.5 Small exploration programs conducted between 2019 and 2021 on the northwestern side of the mountain included soil sampling, rock sampling, mapping, and shallow drilling campaigns. These programs successfully identified a 2 km soil anomaly which appears to be related to a vein system of roughly the same strike length. Drill testing of the exposed vein confirmed continuity of mineralization coincidental with the soil anomaly.6
The MYAB Permit allows the Company to carry out the following exploration activities over the next five years in the areas shown below (Fig. 2):
30 drill holes
1,400 m of trenching
4,500 m of trail building
20 km of geophysical surveys with exposed electrodes
To view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/4873/254869_f589e05a049e09e2_003full.jpg
Figure 2. Site map with MYAB Permit boundaries
Peter Espig, CEO of Nicola Mining Inc., commented, "Receipt of the MYAB under Permit Number MX-15-121 coupled with our recently received ten-year mine life extension under Permit M-239, puts Nicola into an envious position as the confluence of mine and exploration potential brings forth a project that most investors have forgotten. Bolstered by solid silver prices and with permits in hand, we are very excited about its potential and look forward to exploring our Treasure Mountain Project for the first time in over a decade"
Qualified PersonWilliam Whitty, P. Geo., the Company's VP Exploration, is the Qualified Person as defined by National Instrument 43-101 - Standards of Disclosure for Mineral Projects and supervised the preparation of, and has reviewed and approved the technical information in this release.
About Nicola MiningNicola Mining Inc. is a junior mining company listed on the TSX-V Exchange and Frankfurt Exchange that maintains a 100% owned mill and tailings facility, located near Merritt, British Columbia. It has signed Mining and Milling Profit Share Agreements with high-grade BC-based gold projects. Nicola's fully permitted mill can process both gold and silver mill feed via gravity and flotation processes.
The Company owns 100% of the New Craigmont Project, a property that hosts historic high-grade copper mineralization and covers an area of over 10,800 hectares along the southern end of the Guichon Batholith and is adjacent to Highland Valley Copper, Canada's largest copper mine. The Company also owns 100% of the Treasure Mountain Property, which includes 30 mineral claims and a mineral lease, spanning an area exceeding 2,200 hectares.
On behalf of the Board of Directors
"Peter Espig"
Peter EspigCEO & Director
For additional information
Contact: Peter EspigPhone: (778) 385-1213 Email: info@nicolamining.comURL: www.nicolamining.com
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
1 Treasure Mountain Silver Project / Mine: Link2 August 30, 2024, News: Link3 Ostensoe, E. A., Giroux, G. H. and Beaton, A. J., 2009, Technical Report, Resource Estimation, Mining and Reclamation Plan and Economic Evaluation, Treasure Mountain Property, Tulameen River Area, B. C., Canada.4 August 25, 2010, News: Link5 October 7, 2013, News: Link6 Assessment Report for 2021 Exploration
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/254869
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 hours ago
- Yahoo
GTT: Main terms and conditions of the share buy-back programme
GAZTRANSPORT ET TECHNIGAZSociété anonyme with a share capital of €371,177.72Registered office: 1 route de Versailles – 78470 Saint-Rémy-lès-Chevreuse, France662 001 403 R.C.S. Versailles Main terms and conditions of the share buy-back programme in accordance with the conditions and obligations set by Articles 241-1 and seq. of the General Regulations of the (AMF) Implementation of the share buy-back programme authorised by the Combined Shareholders' meeting on June 11, 2025 Issuer: GTT / ISIN code: FR 0011726835 (compartment A) Stock concerned : Ordinary shares Implementation authorized by: Combined Shareholders' meeting on June 11, 2025 Implementation decision date: June 11, 2025 Maximum proportion of the share capital that may be acquired pursuant to the Shareholders' authorization: 10% of the number of ordinary shares composing GTT's share capital, or, for indicative purposes 3,711,777 shares on the basis of the capital as at December 31, 2024. It is specified that: (i) the number of shares acquired for retention and their subsequent presentation in a merger, split or contribution transaction cannot exceed 5% of its share capital; (ii) when the shares are bought back to improve liquidity under the conditions defined by the general regulations of the Autorité des Marchés Financiers (AMF), the number of shares used for calculating the above-specified 10% limit corresponds to the number of shares bought, less the number of shares sold, during the period of the authorisation; (iii) the Company may not directly or indirectly own more than 10% of its capital. Maximum purchase price: €190 per share (fees not included). Maximum amount of purchases authorized by the programme: €705,237,630. Objectives of the programme: the implementation of (i) share purchase option plans or (ii) free share award plans, or (iii) the allocation or sale of shares to employees or corporate officers of the Company or of Group companies under the conditions and in accordance with the procedures allowed by law, notably with respect to Company profit-sharing; or the implementation of any employee savings scheme under the conditions provided for by law, specifically Articles L. 3332-1 et seq. of the French Labour Code, the sale of shares previously acquired by the Company pursuant to this resolution or providing for the free allocation of these shares in the form of a top-up of Company securities and/or to replace the discount, or (iv) any other form of award, allocation or transfer to employees and/or corporate officers of the Company or affiliated companies; the delivery of shares upon the exercise of rights attached to securities giving right to repayment, conversion, exchange, presentation of a warrant, or any other means of allocating shares of the Company; the retaining and later delivery of shares (in exchange, payment or other) as part of an acquisition transaction, limited to 5% of the number of shares comprising the share capital; the cancellation of all or part of the shares bought back under a resolution of a Shareholders' Meeting in force; and the stimulation of the secondary market or the liquidity of the shares by an investment services provider acting under a liquidity contract in compliance with the market practice recognised by the Autorité des Marchés Financiers. This share buyback program would also be intended to allow the Company to operate for any other permitted purpose or which would become permitted by any applicable laws or regulations in force and to implement any practice that would be allowed by the Autorité des Marchés Financiers. In such event, the Company would inform its shareholders through a press release. The acquisition, sale or transfer of shares may be carried out, on one or more occasions, by any means authorised by the legal and regulatory provisions in force, on regulated markets, multilateral trading facilities, systematic internalisers or over-the-counter, including by acquisition or sale of blocks of shares (without limiting the portion of the buyback program that may be carried out by this means), by tender offer or exchange offer, or by use of options or other forward financial instruments or by delivery of shares following the issue of securities giving access to the Company's capital by conversion, exchange, redemption, exercise of a warrant or in any other manner, either directly or indirectly through an investment services provider. The Board of Directors may use this authorisation at any time, within the limits authorised by legal and regulatory provisions and those provided for in the 16th resolution of the Annual General Meeting held on June 11, 2025 (except during a period of tender offer filed by a third party for the Company's shares). Programme duration: from the release of this description of the programme and until December 10, 2026, i.e. a period of 18 months as from the date of the Combined Shareholders' meeting dated June 11, 2025. Breakdown of the treasury shares held: As at June 11, 2025, the Company holds 2,250 shares as part of its liquidity agreement signed with Rothschild Martin Maurel for the purpose of stimulating the market in GTT shares, and compliant with the ethical charter recognised by the AMF, and holds 50,285 shares outside the liquidity, representing a total of 0.14 % of the share capital . This document is published on June 12, 2025, in accordance with the AMF General Regulations, prior to the implementation of the programme. Attachment GTT - PR Main terms and conditions of the share buy-back programme 2025 ENSign in to access your portfolio
Yahoo
4 hours ago
- Yahoo
NBPE
NB Private Equity Partners Announces the Results of the Annual General Meeting St Peter Port, Guernsey 12 June 2025 NB Private Equity Partners Limited (the 'Company') is pleased to announce that at the Annual General Meeting of its Class A Shareholders held at 1.45 p.m. on 12 June 2025, each of the Resolutions tabled were duly passed without amendment. All resolutions as set out in the Notice of AGM, of which resolutions 1-10 were proposed as ordinary resolutions and resolutions 11 and 12 were proposed as special resolutions, were voted on by way of a poll and the results were as follows: Resolution Votes For % votes cast Votes Against % votes cast Votes Withheld* To receive the Audited Financial Statements and Directors Report for the year ended 31 December 2024. 29,176,689 100% Nil Nil 28,512 To approve the Directors Remuneration Report as set out in the Annual Report for the year ended 31 December 2024. 29,157,113 99.95% 14,774 0.05% 33,314 To re-elect William Maltby as a Director of the Company. 28,884,679 99.01% 289,794 0.99% 30,726 To re-elect Trudi Clark as a Director of the Company. 28,529,372 97.79% 645,101 2.21% 30,726 To re-elect Wilken von Hodenberg as a Director of the Company. 28,907,148 99.08% 267,005 0.92% 31,046 To re-elect Louisa Symington-Mills as a Director of the Company. 28,905,644 99.08% 268,098 0.92% 31,457 To re-elect Pawan Dhir as a Director of the Company. 28,905,637 99.09% 265,967 0.91% 33,595 That KPMG Channel Islands Limited be re-appointed as auditor of the Company. 26,983,892 92.49% 2,190,477 7.51% 30,832 That the Directors may determine the remuneration of the auditors. 28,794,977 98.69% 381,712 1.31% 28,512 That the interim dividend paid on 28 February 2025 of $0.47 per share be approved and ratified. 29,078,022 99.66% 98,614 0.34% 28,565 That the Company be authorised in accordance with Section 315 of the Companies (Guernsey) Law, 2008 (as amended) to make market acquisitions of its ordinary shares in accordance with the terms set out in the Notice of Annual General Meeting. 29,060,885 99.6% 115,804 0.4% 28,512 That the Directors be authorised to allot and issue (or sell from treasury) equity securities for cash, up to an aggregate amount not exceeding 9.99% of the Ordinary Shares in issue. 28,938,707 99.19% 237,715 0.81% 28,779 * A vote withheld is not a vote in law and has not been counted in the votes for and against a resolution. Mr. John Falla retired from the Board upon the conclusion of the Annual General Meeting, and Mr. Dhir takes the role of the Audit Committee Chairman as set out in the Notice of Annual General Meeting. For further information, please contact: NBPE Investor Relations +44 20 3214 9002Luke Mason NBPrivateMarketsIR@ Kaso Legg Communications +44 (0)20 3882 6644 Charles Gorman nbpe@ DampierCharlotte Francis About NB Private Equity Partners LimitedNBPE invests in direct private equity investments alongside market leading private equity firms globally. NB Alternatives Advisers LLC (the 'Investment Manager'), an indirect wholly owned subsidiary of Neuberger Berman Group LLC, is responsible for sourcing, execution and management of NBPE. The vast majority of direct investments are made with no management fee / no carried interest payable to third-party GPs, offering greater fee efficiency than other listed private equity companies. NBPE seeks capital appreciation through growth in net asset value over time while paying a bi-annual dividend. LEI number: 213800UJH93NH8IOFQ77 About Neuberger Berman Neuberger Berman is an employee-owned, private, independent investment manager founded in 1939 with over 2,800 employees in 26 countries. The firm manages $515 billion of equities, fixed income, private equity, real estate and hedge fund portfolios for global institutions, advisors and individuals. Neuberger Berman's investment philosophy is founded on active management, fundamental research and engaged ownership. Neuberger Berman has been named by Pensions & Investments as the #1 or #2 Best Place to Work in Money Management for each of the last eleven years (firms with more than 1,000 employees). Visit for more information. Data as of March 31, in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
4 hours ago
- Yahoo
GenSight Biologics Reaches Agreement with ANSM for Opening of LUMEVOQ® Named Early Access Program (AAC) in France
Agreement to consider opening the French Early Access Program expeditiously after approval of a dose-ranging study Design for dose-ranging study submitted, with clinical trial application targeted for Q3 2025 Opening of AAC targeted for Q4 2025 at the latest Multiple near-term value catalysts expected over next 12 months PARIS, June 12, 2025--(BUSINESS WIRE)--Regulatory News: GenSight Biologics ("GenSight Biologics" or the "Company") (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced that it has reached agreement with the French medicines safety agency ANSM to consider expeditiously opening the French named early access program (AAC) for LUMEVOQ® upon approval of a dose-ranging clinical study. Clear Path Forward for LUMEVOQ® AAC Program in France Following extensive discussions, GenSight reached alignment with ANSM on a plan to open the LUMEVOQ® AAC program. The agency has agreed that the authorization of a focused dose-ranging study could enable the opening of the early access program. The Company has submitted a preliminary design of the study to the agency and aims to finalize the protocol of a dose-ranging study in Q3 2025. In parallel, the Company will work with the agency to find a solution for patients who may not be included in the study but who may benefit from the AAC program. The AAC program is targeted to open in Q4 2025 at the latest. "In the interest of clearing the way for patients to be treated with LUMEVOQ, we are pleased to have achieved this important agreement with ANSM on a clear path forward for opening patient access to LUMEVOQ in France" said Laurence Rodriguez, Chief Executive Officer of GenSight Biologics. "We are thankful for the ANSM's ongoing engagement and openness to discussion, as we work towards the shared goal of providing access to LHON patients who urgently need a safe and effective treatment." Financing Strategy to Support Regulatory Milestones GenSight is implementing a financing strategy to bridge operations through the opening of the AAC program and prepare for the new global Phase III clinical trial. The Company is actively pursuing various funding initiatives to support these critical regulatory milestones. "We are working on our financing strategy to manage the bridge between now and the opening of the AAC program and the initiation of the Phase III study," commented Jan Eryk Umiastowski, CFO of GenSight Biologics. "Our focus remains on securing the resources needed to execute our regulatory strategy while exploring additional funding opportunities. " Advancing Core Marketing Authorization Strategy In parallel with the French AAC program developments, GenSight will continue to advance its global marketing authorization strategy: Preparation for regulatory consultations in the US and EU Planning for the global Phase III trial scheduled to begin in 2026, designed to meet FDA and EMA requirements Completing the transition to a new manufacturing partner to secure reliable clinical and commercial supply Advancing preparations for MHRA submission in the United Kingdom During this period, the Company will actively pursue additional non-dilutive funding opportunities, including licensing arrangements outside North America and Europe and potential M&A activities. Multiple Value Catalysts GenSight anticipates a number of significant value-creating events in 2025-2026: Q3 2025: Clinical trial application for focused dose-ranging study Q4 2025: Completion of manufacturing tech transfer Q4 2025: Opening of the AAC program Q2 2026: Completion of Phase III trial preparations Early H2 2026: Initiation of global Phase III clinical trial Early H2 2026: pre-submission meeting with MHRA Financial Position The Company received €0.7 million of its Research Tax Credit (CIR) end of May, with the remaining €0.4 million to be paid in July 2025. Based on current operations and projections, GenSight's cash will support operations until mid-July 2025. The Company acknowledges that current funds are insufficient to cover operational requirements for the next 12 months. The planned financing initiatives are designed to extend the cash runway and enable the initiation of the Phase III clinical trial and UK MHRA marketing application for LUMEVOQ®. As of June 12, 2025, the number of outstanding GenSight Biologics shares was 131,466,495 ordinary shares. Risk factors Detailed information regarding the Company, including its business, financial information, results, perspectives and related risk factors are contained (i) in the Company's 2024 Universal Registration Document filed with the AMF on April 8, 2025 under number D.25-0234. This document, as well as other regulated information and all of the Company's press releases, can be accessed on the Company's website ( and/or AMF ( The reader's attention is drawn to the risk factors related to the Company and its activities presented in chapter 3 of its 2024 URD in particular the liquidity risk presented in the chapter 3.1.1. About GenSight Biologics GenSight Biologics S.A. is a clinical-stage biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders. GenSight Biologics' pipeline leverages two core technology platforms, the Mitochondrial Targeting Sequence (MTS) and optogenetics, to help preserve or restore vision in patients suffering from blinding retinal diseases. GenSight Biologics' lead product candidate, GS010 (lenadogene nolparvovec) is in Phase III in Leber Hereditary Optic Neuropathy (LHON), a rare mitochondrial disease that leads to irreversible blindness in teens and young adults. Using its gene therapy-based approach, GenSight Biologics' product candidates are designed to be administered in a single treatment to each eye by intravitreal injection to offer patients a sustainable functional visual recovery. Forward-Looking Statements This press release contains forward-looking statements, including statements regarding product development prospects and financial projections. These statements do not constitute guarantees of future performance and involve risks and uncertainties. While the Company is actively pursuing financing solutions, regulatory requirements necessitate disclosure that material uncertainty exists regarding the Company's ability to continue as a going concern if sufficient funding cannot be secured. A further list and description of risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements in this press release can be found in GenSight Biologics' regulatory filings with the French Autorité des Marchés Financiers. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements and estimates, which speak only as of the date hereof. Other than as required by applicable law, GenSight Biologics undertakes no obligation to update or revise the information contained in this press release. View source version on Contacts GenSight Biologics Chief Financial Officer Jan Eryk Umiastowski jeumiastowski@
